TRPM7 has been indicated as a potential therapeutic target for GBM [4–7] in addition to other cancer types, including: pancreatic cancer, leukemia, head and neck cancer, prostate cancer, retinoblastoma, nasopharyngeal cancer, gastric cancer, ovarian cancer, and breast cancer [8–13]. This evidence concerns the gene TRPM7 and glioblastoma.